Patient Engagement and Patient Experience Data: Understanding the Use in Medicines Regulation and Healthcare Decision Making and the Implications for Medical Affairs

The role of Medical Affairs (MA) has evolved from liaising with HCPs to playing a more prominent role in partnering across the healthcare system to achieve outcomes that are more meaningful for patients, family members and caregivers. For MA and their internal partners, the risk of involving patients in medicines development has shifted to the risk of NOT involving patients.

Involvement of patients in post-launch activities needs further consideration. To better understand what matters most to patients, patient experience data (PED) plays a critical role in the drug development lifecycle, including considering real world data (RWD) after launch. PE & PED helps to steer MA and colleagues toward focusing on outcomes that patients care about, guiding them towards developing relevant evidence that supports healthcare and regulatory decisions and better engage them in post-launch activities.

This webinar will discuss how MA colleagues are best positioned to explore the fusion of PE and PED in the post-launch phase, including generation and use of RWD and RW evidence, and will share guidance and information on several industry-supported resources, to enable MA colleagues to implement PE and evidence strategies in their function. Importantly, patient and patient advocate perspectives will also be considered, sharing opportunities, and best practice examples of how MA colleagues can overcome perceived barriers, to achieve true and impactful PE.

Objectives:

Following the presentation, participants will have a greater understanding of:

– Current best practice in patient engagement, from both an industry, patient advocate and patient perspective

– The convergence of patient experience data, real world evidence and patient engagement activity and why this is important to Medical Affairs

– What patients and their advocates need from their industry partners for better patient engagement and how this is likely to evolve

– The specific impact patient engagement can have on a Medical Affairs strategy and the various research, tools and guidance available to support this

Moderator

Michael Parisi

Michael Parisi, Global President, Medical Strategy & Communications, Lumanity

Speaker:

Nicholas Brooke

Founder and Executive Director, The Synergist, and Executive Director, Patient Focused Medicines Development (PFMD)

Speaker:

Susan Stein

Executive Director Medical Affairs Patient Advocacy

TP Therapeutics/BMS

Speaker:

Professor Lara Bloom

President and CEO,

The Ehlers-Danlos Society